Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jan 8:2021:8886210.
doi: 10.1155/2021/8886210. eCollection 2021.

Rivaroxaban: Expanded Role in Cardiovascular Disease Management-A Literature Review

Muhammad Ajmal  1 , Jacob Friedman  1 , Qurat Ul Ain Riaz Sipra  1 , Tom Lassar  1
Affiliations
Review

Rivaroxaban: Expanded Role in Cardiovascular Disease Management-A Literature Review

Muhammad Ajmal et al. Cardiovasc Ther. .

Abstract

Direct oral anticoagulants (DOACs) are widely used for the prevention of stroke in nonvalvular atrial fibrillation, treatment of deep venous thrombosis and pulmonary embolism, and as prophylaxis after hip and knee surgery after approval by the Food and Drug Administration. In the last decade, DOACs were studied for various indications; this review is focused on rivaroxaban, a factor Xa inhibitor, which is used in an expanded evidence-based fashion for coronary artery disease, peripheral artery disease, heart failure, malignancy, and prophylaxis of deep venous thrombosis in acute medical illnesses.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflicts of interest.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Mueck W., Stampfuss J., Kubitza D., Becka M. Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban. Clinical Pharmacokinetics. 2014;53(1):1–16. doi: 10.1007/s40262-013-0100-7. - DOI - PMC - PubMed
    1. Cabral K. P., Ansell J. E. The role of factor Xa inhibitors in venous thromboembolism treatment. Vascular Health and Risk Management. 2015;11:117–123. doi: 10.2147/VHRM.S39726. - DOI - PMC - PubMed
    1. Ajmal M., Naik H., Kocheril A. Left atrial appendage closure in patients with intracranial hemorrhage and nonvalvular atrial fibrillation. Journal of Stroke and Cerebrovascular Diseases. 2020;29(4):p. 104685. doi: 10.1016/j.jstrokecerebrovasdis.2020.104685. - DOI - PubMed
    1. Amerena J., Ridley D. An update on anticoagulation in atrial fibrillation. Heart, Lung & Circulation. 2017;26(9):911–917. doi: 10.1016/j.hlc.2017.05.131. - DOI - PubMed
    1. Mtwesi V., Amit G. Stroke prevention in atrial fibrillation. The Medical Clinics of North America. 2019;103(5):847–862. doi: 10.1016/j.mcna.2019.05.006. - DOI - PubMed

MeSH terms

LinkOut - more resources